Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab

NCT07000110 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07000110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07000110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
January 26, 2026
Completion date
November 30, 2031
Enrollment
3,506 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus